USA flag logo/image

An Official Website of the United States Government

A Nanocrystal Biosensor for Detection of Multiple TBI Neurochemical Biomarkers

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85915
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
NS056848
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NANOMATERIALS AND NANOFABRICATION LABORATORIES
P.O. Box 2168 Fayetteville, AR 72702 2168
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: A Nanocrystal Biosensor for Detection of Multiple TBI Neurochemical Biomarkers
Agency: HHS
Contract: 1R43NS056848-01A1
Award Amount: $199,984.00
 

Abstract:

DESCRIPTION (provided by applicant): This SBIR proposal intends to develop a nanocrystal biosensor, which is capable of simultaneously detecting and quantifying multiple traumatic brain injury (TBI)-specific biomarkers in relatively small volumes of whole blood (0.1-1 uL). The biosensor design utilizes the well-known size dependent photoluminescence (PL) of the semiconductor nanocrystals to label monoclonal antibodies for these brain injury-specific biomarkers such as S-100a, D- Dimer, and CRP, etc . The s emiconductor nanocrystals as biolabels make the biosensor able to simultaneously detect multiple TBI-specific neurochemical biomarkers in one setup with a single light source due to their broad excitation spectra, and their narrow, symmetric emission spect ra. A membrane filter, immobilized with multiple monoclonal antibodies, will be used as a bioseparator to specifically capture and separate these multiple TBI-specific neurochemical biomarkers from the sample while going through the microflow cell. The sim ultaneous detection and quantification of multiple brain injury-specific biomarkers will subsequently be accomplished by the differently sized semiconductor nanocrystal biolabeled antibodies. The simultaneous detection of multiple TBI-specific neurochemica l biomarkers diminishes the false signal and improves the accuracy in assessing TBI. In comparison to existing technologies such as ELISA, this new technology will be more sensitive, reliable, specific, accurate, portable, robust, inexpensive and rapider t o assess TBI.

Principal Investigator:

Yongcheng Liu
4795753481
YCLIU@NN-LABS.COM

Business Contact:

Yongcheng Liu
ycliu@nn-labs.com
Small Business Information at Submission:

NANOMATERIALS AND NANOFABRICATION LABS
NANOMATERIALS AND NANOFABRICATION LABS P.O. BOX 2168 FAYETTEVILLE, AR 72702

EIN/Tax ID: 731624630
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No